Qudian Inc.(QD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QD Qudian Inc.

Market Closed 05-17 16:00:00 EDT

1.89

-0.07

-3.57%

盘后1.98

+0.09+4.76%

17:30 EDT

High2.02	Low1.87	Vol435.62K
Open1.97	D1 Closing1.96	Amplitude7.65%
Mkt Cap357.97M	Tradable Cap228.69M	Total Shares189.40M
T/O837.57K	T/O Rate0.36%	Tradable Shares121.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"QD","market":"US","secType":"STK","nameCN":"Qudian Inc.","latestPrice":1.89,"timestamp":1715976000000,"preClose":1.96,"halted":0,"volume":435617,"hourTrading":{"tag":"盘后","latestPrice":1.98,"preClose":1.89,"latestTime":"17:30 EDT","volume":3174,"amount":6007.95,"timestamp":1715981402153},"delay":0,"floatShares":121000000,"shares":189403851,"eps":0.024841,"marketStatus":"Market Closed","change":-0.07,"latestTime":"05-17 16:00:00 EDT","open":1.97,"high":2.02,"low":1.87,"amount":837574.4407121,"amplitude":0.076531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.024841,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1508299200000,"exchange":"NYSE","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":1.96,"preClose":1.96,"latestTime":"06:14 EDT","volume":16006,"amount":31371.76,"timestamp":1715940860349},"postHourTrading":{"tag":"盘后","latestPrice":1.98,"preClose":1.89,"latestTime":"17:30 EDT","volume":3174,"amount":6007.95,"timestamp":1715981402153},"volumeRatio":0.5995625950661053,"overnightSupported":true},"requestUrl":"/m/hq/s/QD","defaultTab":"news","newsList":[{"id":"2435889496","title":"Qudian: 60% Discount To Liquidation Value And Massive Value Creation From Buybacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2435889496","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435889496?lang=en_us&edition=fundamental","pubTime":"2024-05-15 15:13","pubTimestamp":1715757183,"startTime":"0","endTime":"0","summary":"Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more  Guido Mieth Qudian Inc.  is a BUY. It's a severely undervalued asset based on buying liquidation value at a discount. Qudian is sitting on a massive cash stack that keeps the company open to many opportunities within the company and outside the company. The market is currently so pessimistic about Qudian that they are making more money with the share repurchase agreement than the actual business. For almost 5 years, Qudian has been selling as a net-net stock, because of the constant under-performance of the underlying business, and a general mistrust for Chinese companies, in my opinion. You are currently able to buy the company for .40 cents on the dollar based on liquidation value alone!Also, massive value is being unlocked through the two repurchase programs. Just hope the company continues to buy back s","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1478156131/image_1478156131.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1478156131/image_1478156131.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693354-qudian-60-percent-discount-to-liquidation-value-and-massive-value-creation-from-buybacks","is_publish_highlight":false,"gpt_icon":0},{"id":"2435459317","title":"QD Laser FY Parent Loss Y642.00M Vs Loss Y550.00M","url":"https://stock-news.laohu8.com/highlight/detail?id=2435459317","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435459317?lang=en_us&edition=fundamental","pubTime":"2024-05-14 18:05","pubTimestamp":1715681100,"startTime":"0","endTime":"0","summary":"QD Laser Inc.  Japan Year Ended March 31 PARENT20242023 RevenueY1.25 blnY1.16 bln Operating Profit Pretax Profit Net Profit Per share Earnings Dividend First quarterN/AN/A MidyearY0.00Y0.00 Third quarterN/AN/A Year-endY0.00Y0.00 AnnualY0.00Y0.00 Figures in parentheses are losses. Results are based on Japanese accounting standards. Dividends for periods in the future are forecasts.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435585982","title":"Qudian Inc. Welcomes New Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2435585982","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435585982?lang=en_us&edition=fundamental","pubTime":"2024-05-14 05:27","pubTimestamp":1715635627,"startTime":"0","endTime":"0","summary":"Qudian Inc. (QD) has released an update. Qudian Inc., a consumer-oriented technology company, has announced the appointment of Mr. David Cui to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qudian-inc-welcomes-new-board-member?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qudian-inc-welcomes-new-board-member?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435324514","title":"Press Release: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2435324514","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435324514?lang=en_us&edition=fundamental","pubTime":"2024-05-13 20:05","pubTimestamp":1715601900,"startTime":"0","endTime":"0","summary":"Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701  in CML expected in 2H24. Top-line data from Phase 1 trial of TERN-601  for obesity expected in 2H24. Cash, cash equivalents and marketable securities of $241 million, expected to provide runway into 2026. \"We continue to execute our strategy and make important progress on our pipeline of potential best-in-class small molecule therapies as we prepare for key data readouts from our two lead programs,\" said Amy Burroughs, chief executive officer of Terns, \"We look forward to reporting both interim dose escalation data from the ongoing Phase 1 CARDINAL trial of TERN-701 in CML and top-line data from the Phase 1 trial of TERN-601 in obesity in the second half of this year.\". \"We are particularly pleased with the recent findings from our Phase 1 study of TERN-701 in healthy volunteers, which showed lack of food effect and supports once-daily dosing. This represents a key potential differentiator as the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435341307","title":"Press Release: Qudian Inc. Announces Changes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2435341307","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435341307?lang=en_us&edition=fundamental","pubTime":"2024-05-13 17:00","pubTimestamp":1715590800,"startTime":"0","endTime":"0","summary":"XIAMEN, China, May 13, 2024 /PRNewswire/ -- Qudian Inc.  , a consumer-oriented technology company, today announced that Mr. David Cui has replaced Mr. Shengwen Rong as a member of the board of directors , audit committee and compensation committee of the Company.Mr. Shengwen Rong resigned from the Board for personal reasons, effective as of May 11, 2024. Upon recommendation by the nominating and corporate governance committee of the Company, the Board resolved to appoint Mr. David Cui as a director and member of the audit committee and compensation committee to fill the positions vacated by Mr. Shengwen Rong, effective as of May 11, 2024.Mr. Min Luo, Chairman and Chief Executive Officer of the Company stated, \"We would like to express our gratitude to Mr. Rong for his service as a director and as a member of the audit committee and compensation committee. We wish him the best in his future endeavors. We are also delighted to welcome Mr. Cui to t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433727850","title":"Investors in Qudian (NYSE:QD) have seen respectable returns of 91% over the past year","url":"https://stock-news.laohu8.com/highlight/detail?id=2433727850","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2433727850?lang=en_us&edition=fundamental","pubTime":"2024-05-08 21:18","pubTimestamp":1715174325,"startTime":"0","endTime":"0","summary":"If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost returns by picking market-beating companies to own shares in. For example, the Qudian Inc.  share price is up 91% in the last 1 year, clearly besting the market return of around 26% . If it can keep that out-performance up over the long term, investors will do very well!However, the longer term returns haven't been so impressive, with the stock up just 27% in the last three years.So let's assess the underlying fundamentals over the last 1 year and see if they've moved in lock-step with shareholder returns.To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share  and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.Qudian went from making a loss to repor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NPWPwaqd_YNMPuUbekamwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/17286ad821a1799fbe520d67c5c5f1ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NPWPwaqd_YNMPuUbekamwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/17286ad821a1799fbe520d67c5c5f1ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-qudian-nyse-qd-seen-131845478.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431430663","title":"Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2431430663","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2431430663?lang=en_us&edition=fundamental","pubTime":"2024-04-30 19:00","pubTimestamp":1714474800,"startTime":"0","endTime":"0","summary":"– Total revenues of $881 million in the first quarter  . – Jakafi  net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million. – Opzelura  net product revenues of $86 million  in Q1'24; continued uptake in atopic dermatitis  and vitiligo. – Incyte to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists with the potential to treat multiple mast cell-mediated diseases. WILMINGTON, Del., April 30, 2024----Incyte  today reports 2024 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.In February 2024, Incyte announced that the U.S. Food and Drug Administration  accepted for Priority Review the Biologics License Application  for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease  after failure of at least two prior lines of systemic therapy.In April 2024, Incyte and Ch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ro5killaTD4hNXOAiN5QmQ--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/50094731d0a6599e5e406fd6ca95f8bf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ro5killaTD4hNXOAiN5QmQ--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/50094731d0a6599e5e406fd6ca95f8bf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-reports-2024-first-quarter-110000319.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431391718","title":"Qudian Files Its Annual Report on Form 20-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2431391718","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2431391718?lang=en_us&edition=fundamental","pubTime":"2024-04-29 18:30","pubTimestamp":1714386600,"startTime":"0","endTime":"0","summary":"Qudian will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations department, Level 39, Tower A, AVIC Zijin Plaza, Siming District, Xiamen, Fujian Province, The People's Republic of China, 361000.Qudian is a consumer-oriented technology company. The Company historically focused on providing credit solutions to consumers. Qudian is exploring innovative logistics services to satisfy consumers' demand for e-commerce transactions by leveraging its technology capabilities.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XU4Mwp6.ozWBodWlK7MBCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/5aeb7bf53652a8c509a9db82d8d9d20b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XU4Mwp6.ozWBodWlK7MBCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/5aeb7bf53652a8c509a9db82d8d9d20b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/qudian-files-annual-report-form-103000127.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qudian-files-annual-report-form-103000127.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430402270","title":"New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2430402270","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2430402270?lang=en_us&edition=fundamental","pubTime":"2024-04-25 20:00","pubTimestamp":1714046400,"startTime":"0","endTime":"0","summary":"Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance  and no to little itch  at Week 161. LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of those therapies was inadvisable1. The safety profile of upadacitinib was consistent with the profile in previous atopic dermatitis studies with no new safety signals identified during the 16-week period1,2. \"Even while receiving conventional treatments, many patients with atopic dermatitis still continue to live withsignificant itchand inflammatory skin symptoms that can profoundly impact their everyday lives,\" saidRoopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. \"Results from this study show that patients with moderate-to-severe atopic der","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.Xe1EIX7J6bie9vkkSC.wQ--~B/aD03MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.Xe1EIX7J6bie9vkkSC.wQ--~B/aD03MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/data-show-rinvoq-upadacitinib-demonstrated-120000610.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-show-rinvoq-upadacitinib-demonstrated-120000610.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783950","title":"AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783950","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426783950?lang=en_us&edition=fundamental","pubTime":"2024-04-12 19:30","pubTimestamp":1712921400,"startTime":"0","endTime":"0","summary":"NORTH CHICAGO, Ill., April 12, 2024 /PRNewswire/ -- AbbVie  today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.\"Migraine is a debilitating neurological disease that can have a significant impact on day-to-day life,\" said Sait Ashina, MD, assistant professor of neurology and anesthesia at Harvard Medical School, director of the Comprehensive Headache Center at Beth Israel Deaconess Medical Center in Boston, and lead author of the study. \"As the first report of one-year atogepant data in patients with chroni","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23059468","is_publish_highlight":false,"gpt_icon":0},{"id":"2426559012","title":"Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2426559012","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426559012?lang=en_us&edition=fundamental","pubTime":"2024-04-11 19:55","pubTimestamp":1712836500,"startTime":"0","endTime":"0","summary":"Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23054276","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qudian.com","stockEarnings":[{"period":"1week","weight":-0.0957},{"period":"1month","weight":-0.1674},{"period":"3month","weight":-0.2348},{"period":"6month","weight":0.0988},{"period":"1year","weight":0.512},{"period":"ytd","weight":-0.0735}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Qudian Inc. operates as a consumer-oriented technology company in the People's Republic of China. It engages in the operation of online platforms to provide small consumer credit products, as well as provides technology development and services and research and development services. The company was founded in 2014 and is headquartered in Xiamen, the People's Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.097219},{"month":2,"riseRate":0.428571,"avgChangeRate":0.013209},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.003134},{"month":4,"riseRate":0.285714,"avgChangeRate":0.002135},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.091983},{"month":6,"riseRate":1,"avgChangeRate":0.202577},{"month":7,"riseRate":0.5,"avgChangeRate":0.007439},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.093979},{"month":9,"riseRate":0,"avgChangeRate":-0.139118},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042442},{"month":11,"riseRate":0.142857,"avgChangeRate":-0.129083},{"month":12,"riseRate":0.428571,"avgChangeRate":0.012245}],"exchange":"NYSE","name":"Qudian Inc.","nameEN":"Qudian Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Qudian Inc.(QD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Qudian Inc.(QD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Qudian Inc.,QD,Qudian Inc.股票,Qudian Inc.股票老虎,Qudian Inc.股票老虎国际,Qudian Inc.行情,Qudian Inc.股票行情,Qudian Inc.股价,Qudian Inc.股市,Qudian Inc.股票价格,Qudian Inc.股票交易,Qudian Inc.股票购买,Qudian Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Qudian Inc.(QD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Qudian Inc.(QD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction